# Hyperthyroidism

Confirm biochemical thyrotoxicosis, rapidly identify thyroid storm, then distinguish hormone overproduction from destructive or exogenous hormone exposure to select thionamides, definitive therapy, or non-antithyroid management.

**Clinical question:** How should physicians confirm, classify, stabilize, and treat hyperthyroidism and other causes of thyrotoxicosis?

Updated: 2026-08-21T02:10:10.485059+00:00

## What matters in practice
- A low TSH with elevated free T4 or free T4 index establishes biochemical hyperthyroidism; obtain T3 when TSH is low and free T4 is normal to identify T3 thyrotoxicosis. [7][12][13]
- Separate increased hormone synthesis from thyroiditis or exogenous hormone exposure before prescribing a thionamide: uptake imaging, TRAb/TSI, Doppler ultrasound, goiter, and thyroglobulin provide the key branch points. [5][7][9][13]
- Treat suspected thyroid storm immediately with supportive care, beta-blockade, a thionamide, then iodine at least 1 hour later; PTU 500-1,000 mg loading followed by 250 mg every 4 hours is one established regimen. [17][23]
- Methimazole is generally preferred for nonpregnant hyperthyroidism because PTU carries serious hepatotoxicity risk; reserve PTU for the first trimester of pregnancy, methimazole intolerance, or selected thyroid-storm regimens. [18][19][21]
- Radioiodine and thyroidectomy are definitive options for hormone-overproducing disease; radioiodine can transiently worsen thyrotoxicosis and may worsen Graves orbitopathy, particularly in smokers. [10][16]

## Identify thyroid storm and stabilize before etiologic testing

Rapid deterioration in thyrotoxicosis requires intensive treatment rather than outpatient diagnostic sequencing.

Treat severe thyrotoxicosis with rapid clinical deterioration as suspected thyroid storm. Initiate cardiovascular stabilization, respiratory support as needed, temperature control, and evaluation and treatment of precipitating factors while beginning thyroid-directed therapy. [22]

After initial supportive measures, start propranolol 40-80 mg orally every 4-6 hours in suspected thyroid storm unless beta-blockade is clinically unsuitable. Give PTU 500-1,000 mg as a loading dose followed by 250 mg every 4 hours, or methimazole 20 mg every 4-6 hours; PTU additionally inhibits peripheral T4-to-T3 conversion. [23]

Administer iodine only after thionamide therapy: give supersaturated potassium iodide 5 drops orally every 6 hours beginning 1 hour after PTU or methimazole. This sequence avoids providing substrate for new thyroid hormone synthesis before synthesis blockade. [23]
- Use oral, nasogastric, or rectal PTU when enteral delivery is necessary; a total PTU dose of 1,200-1,500 mg/day is described for thyroid storm. [18]
- Use glucocorticoids as part of thyroid-storm pharmacotherapy to reduce peripheral hormone conversion and support adrenal function. [22]
- For refractory severe disease or contraindications to thionamides, therapeutic plasma exchange can be a bridge to radioiodine or thyroidectomy; reported series describe four to six exchanges on average, with daily free T3 and free T4 monitoring. [17]
- Do not plan thyroidectomy before medical control in most thyroid-storm cases; surgery has been proposed when standard therapy fails to improve the patient within 12-24 hours. [22]

*Immediate treatment sequence for suspected thyroid storm. [22][23]*

| Step | Action | Timing or dose |
| --- | --- | --- |
| 1 | Support circulation, respiration, and temperature; identify and treat precipitant. [22] | Immediately. [22] |
| 2 | Start propranolol. [23] | 40-80 mg orally every 4-6 hours. [23] |
| 3 | Block synthesis with PTU or methimazole. [23] | PTU 500-1,000 mg load, then 250 mg every 4 hours; or methimazole 20 mg every 4-6 hours. [23] |
| 4 | Block hormone release with SSKI. [23] | 5 drops orally every 6 hours, starting 1 hour after thionamide. [23] |

## Confirm the biochemical pattern before labeling the cause

TSH establishes the screening branch; free T4 and T3 determine overt versus subclinical disease.

Obtain serum TSH and free T4 (or free T4 index) when hyperthyroidism is suspected. A low TSH with elevated free T4 or free T4 index is the biochemical pattern of hyperthyroidism. TSH is typically less than 0.1 mU/L in overt primary hyperthyroidism and is often less than 0.02 mU/L. [6][12]

If TSH is suppressed but free T4 is normal, obtain total T3 or free T3 to detect isolated T3 thyrotoxicosis. Elevated T3 with normal free T4 represents active overt disease; normal free T4 and T3 with low TSH represents subclinical hyperthyroidism. Free T3 measurement may be less reliable than total T3. [7][12][13]

A low TSH is not always primary thyroid hormone excess. Low or normal TSH together with low free T4 indicates central hypothyroidism rather than hyperthyroidism. During the first trimester, hCG-mediated stimulation can lower TSH; assess overt disease with free T4 or pregnancy-specific total T4 reference ranges. [9][12]
- Review prescribed thyroid hormone, supplements, and iodine exposure before assigning endogenous disease; this can identify exogenous thyroid hormone use or iodine oversupplementation. [13]
- Use thyroid indices obtained close to the time of radionuclide testing because uptake interpretation depends on TSH being suppressed during the study. [7]

*Biochemical patterns that redirect the diagnostic pathway. [6][7][9][12]*

| TSH | Free T4 or FTI | T3 | Interpretation and next action |
| --- | --- | --- | --- |
| Low | Elevated | Usually elevated | Overt hyperthyroidism; determine etiology. [6][12] |
| Low | Normal | Elevated | T3 thyrotoxicosis; manage as overt hyperthyroidism and determine etiology. [7][12] |
| Low | Normal | Normal | Subclinical hyperthyroidism; treatment is more controversial than for overt disease. [7] |
| Low or normal | Low | Not required for classification | Consider central hypothyroidism, not primary hyperthyroidism. [12] |

## Differentiate Graves disease, autonomous nodules, thyroiditis, and exogenous hormone

The critical distinction is increased synthesis versus release or ingestion of preformed hormone.

Increased radioiodine uptake identifies endogenous hormone overproduction and most often reflects Graves disease, toxic multinodular goiter, or toxic adenoma. Graves disease is the most common cause of hyperthyroidism, followed by toxic nodular goiter; thyroiditis is an important alternative cause of thyrotoxicosis. [1][5]

Order TSH-receptor antibodies or thyroid-stimulating immunoglobulin when Graves disease is suspected or radionuclide imaging is unsuitable. Positive TRAb or TSI supports Graves disease; exophthalmos or extraocular muscle involvement further supports Graves orbitopathy. A thyroid uptake scan, TRAb/TSI measurement, and ultrasound are complementary tools for separating Graves disease, toxic multinodular goiter, and toxic adenoma. [9][13][14]

Use radionuclide uptake/scan to distinguish hormone production from transient thyroiditis or factitious thyrotoxicosis when the clinical diagnosis is uncertain. Low uptake with absent goiter and low thyroglobulin favors exogenous thyroid hormone use. In contrast, high uptake points to Graves disease, toxic multinodular goiter, or toxic adenoma. [5][7][8]

Avoid radioactive iodine diagnostic studies in pregnancy. In pregnancy, breastfeeding, or persons trying to conceive, thyroid ultrasound with Doppler blood flow can help distinguish Graves disease from thyroiditis; TRAb or TSI provides an additional non-radiation test. Measure TSI or TRAb at 20-24 weeks' gestation when Graves disease is present to determine the need for increased fetal monitoring. [9][10]
- Graves disease: diffuse autoimmune stimulation; positive TRAb/TSI and orbitopathy favor this branch. [9][14]
- Toxic multinodular goiter or toxic adenoma: high uptake hyperthyroidism from autonomous nodular disease; the scan helps separate these from Graves disease. [5][9]
- Thyroiditis: transient thyrotoxicosis with low uptake; antithyroid drugs do not address release of preformed hormone. [7][9]
- Factitious thyrotoxicosis: low uptake, absent goiter, and low thyroglobulin; investigate thyroid hormone access and use. [7][8]

*Etiologic branch points in biochemically confirmed thyrotoxicosis. [5][7][8][9][13][14]*

| Etiology | Discriminating findings | Next action |
| --- | --- | --- |
| Graves disease | TRAb/TSI positive; orbitopathy supports diagnosis; typically high uptake. [5][9][14] | Use antithyroid therapy for active hormone synthesis; assess definitive-therapy options and orbitopathy implications. [4][10] |
| Toxic multinodular goiter or toxic adenoma | High uptake hyperthyroidism; scan distinguishes autonomous nodular disease from Graves disease. [5][9] | Select antithyroid control while considering radioiodine or surgery for definitive management. [10][24] |
| Thyroiditis | Low uptake indicating transient release rather than overproduction. [7][9] | Do not use thionamide solely to block synthesis; manage the thyrotoxic phase and reassess thyroid function. [7] |
| Exogenous thyroid hormone | Low uptake, absent goiter, low thyroglobulin; antibodies usually absent without prior autoimmunity. [7][8] | Stop or correct hormone exposure and consider supervised serial thyroid testing when covert use is suspected. [8] |

## Use symptom control and thionamides for Graves disease or autonomous hyperthyroidism

Thionamides treat synthesis, not destructive thyroiditis or exogenous hormone exposure.

For symptomatic relief of adrenergic manifestations while definitive biochemical control is pending, use a beta-blocker such as propranolol or atenolol. These agents reduce palpitations, tachycardia, tremor, anxiety, heat intolerance, fatigability, and dyspnea but do not suppress thyroid hormone synthesis. [24]

For Graves disease, methimazole is the usual preferred thionamide outside pregnancy. A cited Graves regimen is methimazole 10-20 mg orally once daily until TSH normalizes; maintenance dosing is 5-15 mg/day. Antithyroid drugs inhibit thyroid peroxidase-dependent hormone synthesis. [19][21]

Counsel every patient receiving methimazole or PTU about serious toxicity. Agranulocytosis occurs in approximately 0.2%-0.5% of patients receiving thionamides. PTU is associated with hepatotoxicity and vasculitis, while methimazole/carbimazole is associated with teratogenicity and pancreatitis. [18][19]

Reserve PTU primarily for the first trimester of pregnancy or when methimazole cannot be tolerated; the FDA boxed warning describes severe and sometimes fatal liver injury with PTU. Switch to methimazole in the second and third trimesters. [18]
- Graves disease: a prolonged antithyroid-drug course, usually at least 12 months, may be used in an effort to induce remission. [19]
- Before radioiodine in severe hyperthyroidism or significant cardiac disease, selective methimazole pretreatment can reduce hormone stores and thyrotoxic complications; discontinue methimazole 3-5 days before I-131 when used. [16]
- Do not extrapolate thionamide treatment to thyroiditis or factitious thyrotoxicosis, because these are low-uptake states without active glandular overproduction. [7][8]

*Thionamide selection and high-consequence safety considerations. [18][19][21]*

| Agent | Preferred setting | Key limitation |
| --- | --- | --- |
| Methimazole | Usual first-line thionamide outside pregnancy; cited Graves dose 10-20 mg once daily. [19][21] | Teratogenicity risk in the first trimester; severe adverse effects include agranulocytosis. [18][19] |
| Propylthiouracil | First trimester of pregnancy, methimazole intolerance, or selected thyroid-storm treatment. [18][23] | Severe hepatotoxicity, including acute liver failure; also associated with vasculitis and agranulocytosis. [18][19] |

## Choose radioiodine or thyroidectomy based on disease branch and treatment tradeoffs

Definitive therapy applies to endogenous hyperthyroidism, not low-uptake destructive or exogenous states.

Radioiodine therapy is an established definitive treatment for hyperthyroidism that reduces thyroid hormone synthesis through targeted beta radiation. It commonly results in permanent hypothyroidism; adverse effects include transient thyroiditis, sialadenitis, xerostomia, and rare secondary malignancy. [10][16]

Anticipate a transient rise in circulating thyroid hormone after I-131 from damaged follicles releasing preformed T3 and T4. In severe hyperthyroidism or significant cardiac disease, use selective methimazole pretreatment, then stop methimazole 3-5 days before radioiodine to avoid reduced treatment efficacy. [16]

Consider orbitopathy when selecting radioiodine for Graves disease. Graves ophthalmopathy may occur or worsen after radioiodine, particularly in smokers and in patients with severe hyperthyroidism. [10]

Thyroidectomy is a definitive alternative when medical therapy is contraindicated or unsuccessful, including severe liver disease or leukopenia precluding thionamides, and can be used after stabilization as a bridge-to-definitive option in refractory severe disease. Patients with thyroid storm should generally be medically controlled before surgery. [17][22]
- For toxic multinodular goiter, radioiodine has been reported to reduce goiter size by about 40%. [10]
- After thyroid storm improves, discontinue iodine, taper and stop glucocorticoids, adjust beta-blockade, titrate thionamide therapy, and pursue radioiodine or thyroidectomy when indicated. [23]
- Shared selection among antithyroid drugs, radioiodine, and surgery should account for etiology, age, disease severity, goiter size, Graves orbitopathy, local resources, and patient preference. [24]

*Definitive-therapy considerations for endogenous hyperthyroidism. [10][16][17][22][24]*

| Option | Potential advantage | Key tradeoff or precaution |
| --- | --- | --- |
| Radioiodine | Definitive biochemical control without reoperation; can reduce toxic multinodular goiter size. [10][16] | Permanent hypothyroidism is common; transient thyrotoxicosis may occur; Graves orbitopathy may worsen, particularly in smokers. [10][16] |
| Thyroidectomy | Definitive option when thionamides cannot be used or severe disease requires a surgical pathway. [17] | In thyroid storm, defer in most cases until medical control; consider only after failure of standard medical therapy in selected cases. [22] |
| Prolonged antithyroid drugs | May induce Graves remission after a course usually lasting at least 12 months. [19] | Requires toxicity surveillance; relapse after antithyroid drugs has been reported more often than after radioiodine or surgery. [24] |

## References
1. Hyperthyroidism — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00278-6/fulltext
2. Subclinical thyroid disease — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60276-6/fulltext?e-page-91fcdc6=2&e-page-92a6feb=5&e-page-76d2096=3&e-page-2e4fdd4=14&e-page-19fe3cd=108
3. Hyperthyroidism in pregnancy — www.thelancet.com — https://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70086-X/abstract
4. Thyrotoxicosis — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60782-4/abstract
5. Hyperthyroidism | Annals of Internal Medicine — annals.org — https://annals.org/article.aspx?articleid=1206703
6. Thyroid Function Test - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/thyroid-function-test
7. Euthyroidism - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/euthyroidism
8. Thyroid Stimulating Immunoglobulin - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/thyroid-stimulating-immunoglobulin
9. Thyroid Peroxidase Antibody - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/thyroid-peroxidase-antibody
10. Diagnosis and Management of Thyrotoxicosis — applications.emro.who.int — https://applications.emro.who.int/imemrf/Egypt_J_Hosp_Med/Egypt_J_Hosp_Med_2017_69_6_2743_2749.pdf
11. Guideline for the prevention, diagnosis and treatment of infertility — iris.who.int — https://iris.who.int/server/api/core/bitstreams/0b4b00be-9412-4d73-a3a9-1fb00874fdb6/content
12. Thyroid Function Tests — www.thyroid.org — https://www.thyroid.org/thyroid-function-tests
13. Thyroid Health Blog: Hyperthyroidism Awareness |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/hyperthyroidism-awareness-diagnosis-options
14. Pediatric Thyroid Function Tests |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/pediatric-thyroid-function
15. ATA Guidelines & Statements |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/professionals/ata-professional-guidelines
16. Radioactive Iodine (I-131) Therapy for Hyperthyroidism and Thyroid Cancer - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK557741
17. Clinical Review and Update on the Management of Thyroid Storm — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9462913
18. Acute and emergency care for thyrotoxicosis and thyroid storm - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5667251
19. Management of thyrotoxicosis: anti thyroid drugs - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK577216
20. The efficiency and safety of methimazole and propylthiouracil in hyperthyroidism — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8322508
21. Methimazole - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK545223
22. Approach to the patient with thyroid storm — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13099200
23. Thyroid Storm - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK448095
24. A multi-center, open label, randomised, parallel-group study to — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/53/NCT03303053/Prot_SAP_000.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.